SI2223684T1 - Farmacevtski sestavek s podaljšanim sproščanjem oktreotidnega acetata - Google Patents

Farmacevtski sestavek s podaljšanim sproščanjem oktreotidnega acetata

Info

Publication number
SI2223684T1
SI2223684T1 SI200830961T SI200830961T SI2223684T1 SI 2223684 T1 SI2223684 T1 SI 2223684T1 SI 200830961 T SI200830961 T SI 200830961T SI 200830961 T SI200830961 T SI 200830961T SI 2223684 T1 SI2223684 T1 SI 2223684T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutical composition
prolonged release
octreotide acetate
octreotide
acetate
Prior art date
Application number
SI200830961T
Other languages
English (en)
Inventor
Duena Antonio Parente
Claudio Savulsky
Garces Josep Garces
Vizcaino Ricard Mis
Original Assignee
Gp Pharm S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gp Pharm S.A. filed Critical Gp Pharm S.A.
Publication of SI2223684T1 publication Critical patent/SI2223684T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
SI200830961T 2007-11-23 2008-11-21 Farmacevtski sestavek s podaljšanim sproščanjem oktreotidnega acetata SI2223684T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200703103A ES2324009B1 (es) 2007-11-23 2007-11-23 Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
PCT/ES2008/000731 WO2009068708A2 (es) 2007-11-23 2008-11-21 Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo
EP08855638A EP2223684B1 (en) 2007-11-23 2008-11-21 Pharmaceutical composition with prolonged release of octreotide acetate

Publications (1)

Publication Number Publication Date
SI2223684T1 true SI2223684T1 (sl) 2013-07-31

Family

ID=40589822

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200830961T SI2223684T1 (sl) 2007-11-23 2008-11-21 Farmacevtski sestavek s podaljšanim sproščanjem oktreotidnega acetata

Country Status (13)

Country Link
US (1) US20110124563A1 (sl)
EP (1) EP2223684B1 (sl)
AR (1) AR069420A1 (sl)
CL (1) CL2008003489A1 (sl)
CY (1) CY1114045T1 (sl)
DK (1) DK2223684T3 (sl)
ES (2) ES2324009B1 (sl)
HR (1) HRP20130447T1 (sl)
PL (1) PL2223684T3 (sl)
PT (1) PT2223684E (sl)
SI (1) SI2223684T1 (sl)
TW (1) TWI463991B (sl)
WO (1) WO2009068708A2 (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180054627A (ko) 2015-09-21 2018-05-24 테바 파마슈티컬스 인터내셔널 게엠베하 서방형 올란자핀 제제
US11266608B2 (en) 2015-09-25 2022-03-08 Jennifer J. Kang-Mteler Biodegradable extended release microsphere-hydrogel ocular drug delivery system and method
US10980882B2 (en) * 2015-09-25 2021-04-20 Jennifer J. KANG-MIELER Biodegradable microsphere-hydrogel ocular drug delivery system
US10646443B2 (en) 2017-03-20 2020-05-12 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
EP3655038A1 (en) 2017-07-17 2020-05-27 Medincell Pharmaceutical composition
FR3079421A1 (fr) * 2018-03-28 2019-10-04 Edix Sa Presentations injectables, seringues et compositions a liberation prolongee et/ou controlee de lanreotide
EP4277661A1 (en) 2021-01-18 2023-11-22 Anton Frenkel Pharmaceutical dosage form
WO2023281406A1 (en) 2021-07-06 2023-01-12 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
AU2022390573A1 (en) * 2021-11-22 2024-05-16 SpecGx LLC Injectable sustained release pharmaceutical composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0190833B1 (en) * 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Method for producing microcapsule
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
SE9100610D0 (sv) * 1991-03-04 1991-03-04 Procordia Ortech Ab Bioresorbable material for medical use
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6214792B1 (en) * 1996-04-12 2001-04-10 David Lew Simon Method for treating acute and severe diarrhea
DE19621533A1 (de) * 1996-05-29 1997-12-04 Bosch Gmbh Robert Elektromotorische Bremsvorrichtung
US6150333A (en) * 1998-07-30 2000-11-21 Biomeasure, Inc. Methods of using a somatostatin analogue
ES2169980B1 (es) * 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
KR100466637B1 (ko) * 2003-06-26 2005-01-13 주식회사 펩트론 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법
JP5165239B2 (ja) * 2003-07-15 2013-03-21 ピーアール ファーマシューティカルズ， インコーポレイテッド 制御放出処方物の調製のための方法
PL1968549T3 (pl) * 2005-12-22 2014-10-31 Novartis Ag Preparat o podtrzymywanym uwalnianiu zawierający okterotyd i dwa lub większą liczbę polimerów typu poli(mleczan-co-glikolan)

Also Published As

Publication number Publication date
ES2414472T3 (es) 2013-07-19
CL2008003489A1 (es) 2009-05-29
DK2223684T3 (da) 2013-06-17
ES2324009A1 (es) 2009-07-28
TW200936157A (en) 2009-09-01
HRP20130447T1 (en) 2013-06-30
EP2223684B1 (en) 2013-03-27
TWI463991B (zh) 2014-12-11
ES2324009B1 (es) 2010-05-21
PL2223684T3 (pl) 2013-08-30
WO2009068708A3 (es) 2009-07-16
CY1114045T1 (el) 2016-07-27
EP2223684A2 (en) 2010-09-01
PT2223684E (pt) 2013-06-20
US20110124563A1 (en) 2011-05-26
WO2009068708A8 (es) 2010-10-21
WO2009068708A2 (es) 2009-06-04
AR069420A1 (es) 2010-01-20

Similar Documents

Publication Publication Date Title
IL275854A (en) Pharmaceutical composition and its administration
HK1216232A1 (zh) 控釋藥物組合物
HRP20130447T1 (en) Pharmaceutical composition with prolonged release of octreotide acetate
IL202103A0 (en) Controlled release pharmaceutical compositions for prolonged effect
IL200790A0 (en) Pharmaceutical composition
EP2591773A4 (en) TEMPORARY RELEASED PHARMACEUTICAL COMPOSITION WITH DAPOXIN FOR ORAL ADMINISTRATION
EP2236149A4 (en) MEDICAL COMPOSITION
EP2226071A4 (en) COMPOSITIONS FOR ORAL ADMINISTRATION
GB2454567B (en) Anti-malarial pharmaceutical composition
HK1162936A1 (en) Solid pharmaceutical formulation with delayed release
ZA201102715B (en) Solid pharmaceutical composition
ZA201100871B (en) Solid pharmaceutical composition
EP2327406A4 (en) STABILIZED PHARMACEUTICAL COMPOSITION
ZA201102405B (en) Pharmaceutical composition for oral administration
HK1182939A1 (en) Stable pharmaceutical composition
IL178378A0 (en) Extended release pharmaceutical compositions
HU0700172D0 (en) Sustained release pharmaceutical preparation
ZA201001127B (en) Pharmaceutical formulation for extended release
IL198994A0 (en) Use of incensole and incensole acetate for the preparation of pharmaceutical compositions